ClinicalTrials.gg
CompletedNCT03968978PATH-HOMEUpdated Jul 29, 2021Results posted

Tezepelumab Home Use Study

A Phase 3 interventional study of Tezepelumab (APFS) and Tezepelumab (AI) in Asthma, sponsored by AstraZeneca. Completed at 36 sites in 4 countries. Open to participants aged 12 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-07-29.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
12 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing tezepelumab in Asthma — 7 open to participants now, 8 under way, 5 of them phase 3. tezepelumab · Asthma.

Enrollment
12th of 28
216 · median 121
Started
2019
with 4 others
Phase 3
16 of 28
4 open now
Registered
10th of 28
by date
Lead sponsor
16 of 28
AstraZeneca

Among the 28 studies testing tezepelumab in Asthma, this one is the 12th largest by enrollment, is one of 5 that started in 2019, is one of 16 in phase 3, and was the 10th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 28 studies testing tezepelumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tezepelumab

tezepelumab: first FDA approval 2021 (TEZSPIRE), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing tezepelumab in Asthma, or all of them as a file.
02

Study summary

This is a multicenter, randomized, open-label, parallel-group study designed to assess healthcare provider and subject/caregiver reported functionality and performance of a single-use accessorized pre-filled syringe (APFS) or autoinjector (AI) with a fixed 210 mg dose of tezepelumab administered subcutaneously in the clinic and in an at-home setting.

Read the detailed description

The study will consist of a screening/run-in period of up to 2 weeks and a treatment period of 24 weeks, followed by a post-treatment follow-up period of 12 weeks. During the treatment period, one dose of 210 mg tezepelumab will be administered via a single-use APFS or AI subcutaneously (SC) every 4 weeks (Q4W) starting at Visit 2 (Week 0) until Visit 7 (Week 20). Subjects will be administered tezepelumab at the site during Visits 2 (Week 0), 3 (Week 4), 4 (Week 8) and 7 (Week 20). At-home administration of tezepelumab will occur during Visit 5 (Week 12) and Visit 6 (Week 16). Each device will be assessed separately using descriptive presentations.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma, Severe Uncontrolled Asthma
04

Who can participate

Ages eligible
12 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, age 12 to 80 years.
  • Documented physician-diagnosed asthma for at least 12 months.
  • Evidence of asthma as documented by post BD (albuterol/salbutamol) reversibility of ≥ 12% AND ≥200 mL (15-60 min after administration of 4 puffs of albuterol/salbutamol), documented either: in the previous 12 months prior to V1, OR demonstrated at V1, V1A, or at V2.
  • Documented history of current treatment with medium- or high-dose ICS for at least 6 months and at least one additional asthma controller medication according to standard practice of care. ICS dose must be greater than or equal to 500 μg/day fluticasone propionate dry powder formulation or equivalent daily.
  • Morning pre-BD FEV1 of >50% predicted normal at Visit 1, Visit 1A, or Visit 2.

Exclusion criteria

Exclusion Criteria:

  • pulmonary or systemic diseases other than asthma.
  • History of cancer except basal cell carcinoma, squamous cell carcinoma, or in situ carcinoma of the cervix within 12 months prior to Visit 1.
  • Acute upper or lower respiratory infection requiring antibiotics or antiviral medications finalized \<2 weeks before Visit 1 or during screening/run-in period.
  • A helminth parasitic infection diagnosed within 6 months that is untreated or is unresponsive to the standard of care.
  • Smoking history of ≥10 pack years, (includes vaping and e-cigarettes)
  • History of chronic alcohol or drug abuse.
  • Tuberculosis requiring treatment within 12 months prior to V1.
  • History of , or .
  • Receipt of any marketed or biologic agent within 4 months or 5 half-lives (whichever is longer) prior to visit 1 or receipt of any investigational non-biologic agent within 30 days or 5 half-lives.
  • Bronchial thermoplasty in 24 months prior to V1.
  • Anaphylaxis or documented immune complex disease (Type III reactions) to any biologic therapy.
  • Evidence of active liver disease (e.g. jaundice, , ALT or ALP >2 times ), ongoing liver disease or inexplicably elevated liver chemistry values.
  • Pregnant, breastfeeding or lactating women.
  • Non-leukocyte depleted whole blood transfusion in 120 days prior to visit 1.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
216 participants (actual)

Study arms

  • Experimental
    Tezepelumab (AI)

    Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.

    Biological: Tezepelumab (AI)

  • Experimental
    Tezepelumab (APFS)

    Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).

    Biological: Tezepelumab (APFS)

Interventions

  • Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).

  • Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.

06

What researchers measure

Primary outcomes

  1. Proportions of HCPs and Subjects/Caregivers Who Successfully Administered Tezepelumab in Clinic or at Home by Device Type

    Successful administration is defined as an injection completed, based on a used/returned (HCP or subject/caregiver) answer of YES to all 5 questions in the administration questionnaire, and satisfactory in vitro evaluation of returned/evaluated devices.

    Time frame: Week 0, Week 4, Week 8, Week 12, Week 16, Week 20

Secondary outcomes

  1. Proportions of Used/Returned Devices That Pass Functional Tests and Visual Inspection and Showed no Evidence of Malfunction

    Devices that passed functional tests and visual inspection and showed no evidence of malfunction will be evaluated as functional. Percentages have been calculated by using the number of used and returned devices at specified visit as denominator. Note: A few participants had missing devices. One participant had two AI devices at Week 4.

    Time frame: Week 0, Week 4, Week 8, Week 12, Week 16, Week 20

  2. Proportions of Devices That Have Been Reported as Malfunctioning (Product Complaints)

    Performance is measured by the proportion of APFS or AI devices that have been reported as malfunctioning (i.e. via Product Complaints). Percentages have been calculated by using the number of used and returned devices at specified visit as denominator. Note: A few participants had missing devices. One participant had two AI devices at Week 4.

    Time frame: Week 0, Week 4, Week 8, Week 12, Week 16, Week 20

  3. Change From Baseline in Asthma Control Questionnaire-6 (ACQ-6) Score

    The ACQ-6 captures asthma symptoms and short-acting β2-agonist use via subject-report. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses.

    Time frame: Baseline (Week 0), Week 4, Week 8, Week 12, Week 16, Week 20 and Week 24

  4. Serum Trough Concentrations

    PK serum samples were collected pre-dose on dosing visits

    Time frame: Baseline (Week 0), Week 4, Week 20 and Week 24 (EOT)

  5. Anti-drug Antibodies (ADA)

    Anti-drug antibodies (ADA) responses at baseline and/or post baseline. Treatment-induced ADA positive is defined as ADA negative at baseline and post-baseline ADA positive. Treatment-boosted ADA positive is defined as baseline positive ADA titre that was boosted to a 4-fold or higher-level following IP administration. Treatment-emergent ADA (TE-ADA) positive is defined as either treatment-induced ADA positive or treatment-boosted ADA positive. ADA incidence is the proportion of TE-ADA positive subjects in a population. Persistently positive is defined as ADA positive at \>=2 post-baseline assessments (with \>=16 weeks between first and last positive) or ADA positive at last post-baseline assessment. Transiently positive is defined as having at least one post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive

    Time frame: Pre-treatment on dosing days until end of follow-up (Week 36) per protocol

07

Results

Posted Jul 29, 2021

Participant flow

216 subjects randomized in the study.

Participant flow — Overall Study
MilestoneTeze 210 mg Q4W Via APFSTeze 210 mg Q4W Via AI
Started111105
Completed110105
Not completed10
Withdrew: Adverse event10

Outcome measures

PrimaryProportions of HCPs and Subjects/Caregivers Who Successfully Administered Tezepelumab in Clinic or at Home by Device Type

Successful administration is defined as an injection completed, based on a used/returned (HCP or subject/caregiver) answer of YES to all 5 questions in the administration questionnaire, and satisfactory in vitro evaluation of returned/evaluated devices.

Time frame:
Week 0, Week 4, Week 8, Week 12, Week 16, Week 20
Reported as:
Count of participants · Participants
Proportions of HCPs and Subjects/Caregivers Who Successfully Administered Tezepelumab in Clinic or at Home by Device Type
ParticipantsTeze 210 mg Q4W Via APFSTeze 210 mg Q4W Via AI
Week 0 (in clinic)109105
Week 4 (in clinic)111102
Week 8 (in clinic)110103
Week 12 (at home)110104
Week 16 (at home)104102
Week 20 (in clinic)105102
Statistical analysis
  • Teze 210 mg Q4W Via APFS · Score CI · Proportion: 98.2 · 95% CI 93.67 to 99.5CI at Week 0 (in clinic)
  • Teze 210 mg Q4W Via APFS · Score CI · Proportion: 100 · 95% CI 96.65 to 100CI at Week 4 (in clinic)
  • Teze 210 mg Q4W Via APFS · Score CI · Proportion: 100.0 · 95% CI 96.63 to 100.00CI for Week 8 (in clinic)
  • Teze 210 mg Q4W Via APFS · Score CI · Proportion: 100.0 · 95% CI 96.63 to 100.00CI for Week 12 (at home)
  • Teze 210 mg Q4W Via APFS · Score CI · Proportion: 95.4 · 95% CI 89.71 to 98.02CI for Week 16 (at home)
  • Teze 210 mg Q4W Via APFS · Score CI · Proportion: 96.3 · 95% CI 90.94 to 98.56CI for Week 20 (in clinic)
  • Teze 210 mg Q4W Via AI · Score CI · Proportion: 100.0 · 95% CI 96.47 to 100.00CI for Week 0 (in clinic)
  • Teze 210 mg Q4W Via AI · Score CI · Proportion: 97.1 · 95% CI 91.93 to 99.02CI for Week 4 (in clinic)
  • Teze 210 mg Q4W Via AI · Score CI · Proportion: 98.1 · 95% CI 93.32 to 99.48CI for Week 8 (in clinic)
  • Teze 210 mg Q4W Via AI · Score CI · Proportion: 99.0 · 95% CI 94.80 to 99.83CI for week 12 (at home)
  • Teze 210 mg Q4W Via AI · Score CI · Proportion: 97.1 · 95% CI 91.93 to 99.02CI for Week 16 (at home)
  • Teze 210 mg Q4W Via AI · Score CI · Proportion: 97.1 · 95% CI 91.93 to 99.02CI for Week 20 (in clinic)
SecondaryProportions of Used/Returned Devices That Pass Functional Tests and Visual Inspection and Showed no Evidence of Malfunction

Devices that passed functional tests and visual inspection and showed no evidence of malfunction will be evaluated as functional. Percentages have been calculated by using the number of used and returned devices at specified visit as denominator. Note: A few participants had missing devices. One participant had two AI devices at Week 4.

Time frame:
Week 0, Week 4, Week 8, Week 12, Week 16, Week 20
Reported as:
Count of units · Devices
Proportions of Used/Returned Devices That Pass Functional Tests and Visual Inspection and Showed no Evidence of Malfunction
DevicesTeze 210 mg Q4W Via APFSTeze 210 mg Q4W Via AI
Week 0 (in clinic)109105
Week 4 (in clinic)111103
Week 8 (in clinic)110103
Week 12 (at home)110104
Week 16 (at home)104102
Week 20 (in clinic)105102
Statistical analysis
  • Teze 210 mg Q4W Via APFS · Score CI · Proportion: 98.2 · 95% CI 93.67 to 99.50CI at Week 0 (in clinic)
  • Teze 210 mg Q4W Via APFS · Score CI · Proportion: 100.0 · 95% CI 96.65 to 100.00CI at Week 4 (in clinic)
  • Teze 210 mg Q4W Via APFS · Score CI · Proportion: 100.0 · 95% CI 96.63 to 100.00CI for Week 8 (in clinic)
  • Teze 210 mg Q4W Via APFS · Score CI · Proportion: 100.0 · 95% CI 96.63 to 100.00CI for Week 12 (at home)
  • Teze 210 mg Q4W Via APFS · Score CI · Proportion: 97.2 · 95% CI 92.80 to 99.04CI for Week 16 (at home)
  • Teze 210 mg Q4W Via APFS · Score CI · Proportion: 99.1 · 95% CI 94.85 to 99.83CI for Week 20 (in clinic)
  • Teze 210 mg Q4W Via AI · Score CI · Proportion: 100.0 · 95% CI 96.46 to 100.00CI for Week 0 (in clinic)
  • Teze 210 mg Q4W Via AI · Score CI · Proportion: 97.2 · 95% CI 93.38 to 99.48CI for Week 4 (in clinic)
  • Teze 210 mg Q4W Via AI · Other CI · Proportion: 98.1 · 95% CI 93.32 to 99.48CI for Week 8 (in clinic)
  • Teze 210 mg Q4W Via AI · Score CI · Proportion: 100.0 · 95% CI 96.44 to 100.00CI for week 12 (at home)
  • Teze 210 mg Q4W Via AI · Score CI · Proportion: 100.0 · 95% CI 96.37 to 100.00CI for Week 16 (at home)
  • Teze 210 mg Q4W Via AI · Score CI · Proportion: 100.0 · 95% CI 96.37 to 100.00CI for Week 20 (in clinic)
SecondaryProportions of Devices That Have Been Reported as Malfunctioning (Product Complaints)

Performance is measured by the proportion of APFS or AI devices that have been reported as malfunctioning (i.e. via Product Complaints). Percentages have been calculated by using the number of used and returned devices at specified visit as denominator. Note: A few participants had missing devices. One participant had two AI devices at Week 4.

Time frame:
Week 0, Week 4, Week 8, Week 12, Week 16, Week 20
Reported as:
Count of units · Devices
Proportions of Devices That Have Been Reported as Malfunctioning (Product Complaints)
DevicesTeze 210 mg Q4W Via APFSTeze 210 mg Q4W Via AI
Week 0 (in clinic)20
Week 4 (in clinic)03
Week 8 (in clinic)02
Week 12 (at home)00
Week 16 (at home)30
Week 20 (in clinic)10
Statistical analysis
  • Teze 210 mg Q4W Via APFS · Score CI · Proportion: 1.8 · 95% CI 0.50 to 6.33CI at Week 0 (in clinic)
  • Teze 210 mg Q4W Via APFS · Score CI · Proportion: 0 · 95% CI 0 to 3.35CI at Week 4 (in clinic)
  • Teze 210 mg Q4W Via APFS · Score CI · Proportion: 0 · 95% CI 0 to 3.37CI for Week 8 (in clinic)
  • Teze 210 mg Q4W Via APFS · Score CI · Proportion: 0 · 95% CI 0 to 3.37CI for Week 12 (at home)
  • Teze 210 mg Q4W Via APFS · Score CI · Proportion: 2.8 · 95% CI 0.96 to 7.92CI for Week 16 (at home)
  • Teze 210 mg Q4W Via APFS · Score CI · Proportion: 0.9 · 95% CI 0.17 to 5.15CI for Week 20 (in clinic)
  • Teze 210 mg Q4W Via AI · Score CI · Proportion: 0 · 95% CI 0 to 3.53CI for Week 0 (in clinic)
  • Teze 210 mg Q4W Via AI · Score CI · Proportion: 2.8 · 95% CI 0.97 to 7.99CI for Week 4 (in clinic)
  • Teze 210 mg Q4W Via AI · Other CI · Proportion: 1.9 · 95% CI 0.52 to 6.68CI for Week 8 (in clinic)
  • Teze 210 mg Q4W Via AI · Score CI · Proportion: 0 · 95% CI 0 to 3.56CI for week 12 (at home)
  • Teze 210 mg Q4W Via AI · Score CI · Proportion: 0 · 95% CI 0 to 3.63CI for Week 16 (at home)
  • Teze 210 mg Q4W Via AI · Score CI · Proportion: 0 · 95% CI 0 to 3.63CI for Week 20 (in clinic)
SecondaryChange From Baseline in Asthma Control Questionnaire-6 (ACQ-6) Score

The ACQ-6 captures asthma symptoms and short-acting β2-agonist use via subject-report. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses.

Time frame:
Baseline (Week 0), Week 4, Week 8, Week 12, Week 16, Week 20 and Week 24
Reported as:
Mean · Score
Change From Baseline in Asthma Control Questionnaire-6 (ACQ-6) Score
ScoreTeze 210 mg Q4W Via APFSTeze 210 mg Q4W Via AI
ACQ-6 score at Baseline (Week 0)2.227 ± 0.7322.081 ± 0.625
ACQ-6 score at Week 41.629 ± 0.7911.492 ± 0.715
Change from Baseline of ACQ-6 score at Week 4-0.598 ± 0.702-0.589 ± 0.694
ACQ-6 score at Week 81.401 ± 0.8591.316 ± 0.744
Change from Baseline of ACQ-6 score at Week 8-0.826 ± 0.833-0.765 ± 0.793
ACQ-6 score at Week 121.197 ± 0.7511.143 ± 0.745
Change from Baseline of ACQ-6 score at Week 12-1.011 ± 0.805-0.938 ± 0.805
ACQ-6 score at Week 161.226 ± 0.8451.171 ± 0.782
Change from Baseline of ACQ-6 score at Week 16-0.986 ± 0.893-0.910 ± 0.867
ACQ-6 score at Week 201.230 ± 0.8321.238 ± 0.795
Change from Baseline of ACQ-6 score at Week 20-0.978 ± 0.866-0.843 ± 0.910
ACQ-6 score at Week 241.072 ± 0.7551.140 ± 0.765
Change from Baseline of ACQ-6 score at Week 24-1.141 ± 0.845-0.941 ± 0.775
SecondarySerum Trough Concentrations

PK serum samples were collected pre-dose on dosing visits

Time frame:
Baseline (Week 0), Week 4, Week 20 and Week 24 (EOT)
Reported as:
Geometric mean · µg/mL
Serum Trough Concentrations
µg/mLTeze 210 mg Q4W Via APFSTeze 210 mg Q4W Via AI
Baseline (Week 0)NA ± NANA ± NA
Week 410.9764 ± 48.394810.5690 ± 57.0076
Week 2018.9653 ± 69.078520.3206 ± 56.5858
Week 24 (EOT)19.6274 ± 58.266019.9264 ± 54.3198
SecondaryAnti-drug Antibodies (ADA)

Anti-drug antibodies (ADA) responses at baseline and/or post baseline. Treatment-induced ADA positive is defined as ADA negative at baseline and post-baseline ADA positive. Treatment-boosted ADA positive is defined as baseline positive ADA titre that was boosted to a 4-fold or higher-level following IP administration. Treatment-emergent ADA (TE-ADA) positive is defined as either treatment-induced ADA positive or treatment-boosted ADA positive. ADA incidence is the proportion of TE-ADA positive subjects in a population. Persistently positive is defined as ADA positive at \>=2 post-baseline assessments (with \>=16 weeks between first and last positive) or ADA positive at last post-baseline assessment. Transiently positive is defined as having at least one post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive

Time frame:
Pre-treatment on dosing days until end of follow-up (Week 36) per protocol
Reported as:
Count of participants · Participants
Anti-drug Antibodies (ADA)
ParticipantsTeze 210 mg Q4W Via APFSTeze 210 mg Q4W Via AI
ADA positive at baseline and/or post-baseline (ADA prevalence)211
TE-ADA positive (ADA incidence)28
Treatment-induced ADA positive28
Treatment-boosted ADA positive00
ADA persistently positive17
ADA transiently positive13
Only baseline ADA positive01
Both baseline and at least one post-baseline ADA positive02

Adverse events

Collected over From first dose till end of study (Week 36). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Teze 210 mg Q4W Via APFS0/111 (0%)5/111 (4.5%)29/111 (26.1%)
Teze 210 mg Q4W Via AI0/105 (0%)4/105 (3.8%)29/105 (27.6%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventTeze 210 mg Q4W Via APFSTeze 210 mg Q4W Via AI
AsthmaRespiratory, thoracic and mediastinal disorders0/1113/105
DiverticulitisInfections and infestations2/1110/105
GastritisGastrointestinal disorders0/1111/105
VaricellaInfections and infestations0/1111/105
Psychogenic seizureNervous system disorders0/1111/105
PneumothoraxRespiratory, thoracic and mediastinal disorders0/1111/105
Pancreatitis acuteGastrointestinal disorders1/1110/105
Escherichia urinary tract infectionInfections and infestations1/1110/105
Genitourinary tract infectionInfections and infestations1/1110/105
Pneumonia escherichiaInfections and infestations1/1110/105
Most frequent other events
Most frequent other events
EventTeze 210 mg Q4W Via APFSTeze 210 mg Q4W Via AI
NasopharyngitisInfections and infestations12/11115/105
Upper respiratory tract infectionInfections and infestations9/1118/105
AsthmaRespiratory, thoracic and mediastinal disorders6/1115/105
PharyngitisInfections and infestations4/1114/105

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Teze 210 mg Q4W Via APFSTeze 210 mg Q4W Via AITotal
Mean48.5 ± 18.145.8 ± 18.347.2 ± 18.2
Age, Customized
Age, Customized(Participants)Teze 210 mg Q4W Via APFSTeze 210 mg Q4W Via AITotal
Adolescents (>=12 to <18 years)131124
Adults (>=18 years)9894192
Adults (>=18 to <65 years)7973152
Adults (>=65 years)192140
Sex: Female, Male
Sex: Female, Male(Participants)Teze 210 mg Q4W Via APFSTeze 210 mg Q4W Via AITotal
Female5652108
Male5553108
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Teze 210 mg Q4W Via APFSTeze 210 mg Q4W Via AITotal
White8782169
Black or African American8816
Asian161531
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Teze 210 mg Q4W Via APFSTeze 210 mg Q4W Via AITotal
Hispanic or Latino121325
Not Hispanic or Latino9992191
08

Study locations

36 sites
  • Research Site
    Hoover, Alabama 35244, United States
  • Research Site
    Gilbert, Arizona 85234, United States
  • Research Site
    Northridge, California 91324, United States
  • Research Site
    Palm Desert, California 92260, United States
  • Research Site
    Westminster, California 92683, United States
  • Research Site
    Tampa, Florida 33607, United States
  • Research Site
    Savannah, Georgia 31406, United States
  • Research Site
    Omaha, Nebraska 68114, United States
  • Research Site
    Northfield, New Jersey 08225, United States
  • Research Site
    Cincinnati, Ohio 45231, United States
  • Research Site
    Edmond, Oklahoma 73034, United States
  • Research Site
    Medford, Oregon 97504, United States
  • Research Site
    Dallas, Texas 75235, United States
  • Research Site
    McKinney, Texas 75069, United States
  • Research Site
    San Antonio, Texas 78221, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Calgary, Alberta T2N 1N4, Canada
  • Research Site
    Ajax, Ontario L1S 2J5, Canada
  • Research Site
    Burlington, Ontario L7N 3V2, Canada
  • Research Site
    Mississauga, Ontario L5A 3V4, Canada
  • Research Site
    Ottawa, Ontario K1G 6C6, Canada
  • Research Site
    Windsor, Ontario N8X 2G1, Canada
  • Research Site
    Montreal, Quebec H3G 1L5, Canada
  • Research Site
    Trois-Rivieres, Quebec G8T 7A1, Canada
  • Research Site
    Quebec, G1V 4G5, Canada
  • Research Site
    Quebec, G1V 4W2, Canada
  • Research Site
    Chuo-ku, 103-0027, Japan
  • Research Site
    Fukuoka-shi, 811-1394, Japan
  • Research Site
    Białystok, 15-430, Poland
  • Research Site
    Kraków, 31-011, Poland
  • Research Site
    Poznań, 60-685, Poland
  • Research Site
    Poznań, 60-693, Poland
  • Research Site
    Strzelce Opolskie, 47-100, Poland
  • Research Site
    Tarnów, 33-100, Poland
  • Research Site
    Wieluń, 98-300, Poland
  • Research Site
    Wrocław, 53-301, Poland
09

References and documents

Publications

  • Alpizar S, Megally A, Chen C, Raj A, Downie J, Colice G. Functionality and Performance of an Accessorized Pre-Filled Syringe and an Autoinjector for At-Home Administration of Tezepelumab in Patients with Severe, Uncontrolled Asthma. J Asthma Allergy. 2021 Apr 19;14:381-392. doi: 10.2147/JAA.S305114. eCollection 2021. PubMed 33907423 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Jun 2020, 12 months.

Results were first posted in Jul 2021, 1 year 1 month after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 12 months is below that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2019
First posted
May 30, 2019
StartActual
May 21, 2019
Primary completionActual
Jun 5, 2020
CompletionActual
Jun 5, 2020
Results first posted
Jul 29, 2021
Last update
Jul 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03968978
Lead sponsor
AstraZeneca
Collaborators
Amgen
Responsible party
Sponsor
First posted
May 30, 2019
Start date
May 21, 2019
Primary completion
Jun 5, 2020
Completion
Jun 5, 2020
Results posted
Jul 29, 2021
Last update
Jul 29, 2021

Study contacts

Sady A Alpizar, MD
principal investigator · Clinical Research Trials of Florida, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tezepelumab

Start the discussion